Plain-English translation of NCT07249346 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and —given after a stem cell transplant to prevent a serious complication called graft-versus-host disease (GVHD). In GVHD, immune cells from the transplanted stem cells attack the patient's own body. The study is exploring whether this three-drug approach at lower doses can protect patients better while causing fewer side effects.
GVHD is one of the most serious complications after stem cell transplants, causing pain, organ damage, and sometimes death. Current treatments for preventing it don't always work well or can have significant side effects. This trial is testing whether combining these three medications—particularly at lower doses—might be safer and more effective than existing options.
You likely qualify if…
You likely don't qualify if…
You will receive the three medications starting before your stem cell transplant and continuing for several months afterward. is given as two high-dose infusions on days 3 and 4 after transplant. is taken by mouth and tapered after 3 months. is taken daily starting before transplant, with the dose adjusted based on how your body responds, and continues for up to 6 months. You will have frequent clinic visits and blood tests to monitor for side effects, how well your new immune system is working, and whether your cancer stays controlled.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States